The Trimoryn Journal: Five Pieces About One Label

• Before-and-after stories. There are none. What this desk publishes instead is its whole review roster, including the three-star review and the observation that every published reviewer is a man, on the reviews page.
• A timeline promise. No piece here says how long the capsule takes to work, because the honest answer is a range drawn from buyer feedback rather than from any trial. That range, and what to record while you wait, is on the timeline page.
• The guarantee. A piece on the start date was drafted and dropped: the window is a single precise matter and it belongs in one place rather than two. The guarantee page has it, including why counting from purchase is the shorter of the two readings.
• The category as a whole. These five are about one label. For the aisle rather than the bottle, the category guide collects the five ingredient families and what to expect from each, and the checklist turns it into twelve rows you can apply anywhere.

A journal on a retail website earns its place by being useful to somebody who does not buy anything. That is the standard these five are written to, and it is why the longest of them ends by telling a reader who wants the probiotics to buy a different product.

One note on how to read them. Every piece starts from a panel row rather than a front-of-bottle claim, and the order matters more than it sounds. A front-of-bottle claim is written to be believed; a panel row is written to be checked. The panel itself, transcribed entry by entry, is on the label page, and the ingredients page carries what is known about each of the eleven.

If a line in any of these articles is wrong, that is this desk’s problem rather than yours. Write to the website desk with the post and the line, and the correction is made on the page with the review date moved forward rather than noted somewhere nobody reads.

The same shape five times, because the shape is what makes them checkable rather than persuasive.

• It opens on a row from the printed panel, quoted exactly as the label gives it, including the dagger and the standardisation. Not on a claim from the front of the bottle.
• It names the published work behind that row, with the amount that work actually used, taken from the record rather than from memory. Where the record does not state a dose, the piece says so and offers no arithmetic.
• It does the comparison in public, usually in a table, and prints the fraction whichever direction it runs. One of the five ends with a number that flatters the product and four do not.
• It ends with what a reader should do, which twice is to buy something else.

Every piece carries four to six citations rather than the full site list, because twenty-one sources under a single post reads as padding. Every one of those was fetched from the publisher and swept twice for retractions, once by paper and once by author, and five otherwise clean papers were dropped on the author sweep and replaced.

• How much of a probiotic is a billion? A tenth and a twentieth of the two trials behind the two species on this label.
• Is 45 mg of glucomannan a fibre supplement? No, and the clean trial at ninety times that amount found no weight loss at all.
• Is 1,470% of a Daily Value dangerous? No. Riboflavin has no upper limit set and the visible consequence is bright yellow urine.
• What does 10:1 on a label actually tell you? Roughly how much plant, and nothing about which compounds survived the extraction.
• Who is this product for? The order page says women over forty. The bottle restricts by age and condition and says nothing about sex.

Answering those five honestly is what the journal is for, and three of the five answers are ones a seller would rather not print.

• If the gut claim is why you are here, read the colony-count piece. It ends by telling a reader who wants the probiotics to buy a different product, which is the most useful sentence in the whole journal.
• If you were sold on appetite control, read the glucomannan piece. The one clean trial used ninety times the amount on this panel and found nothing.
• If the 1,470% figure worried you, read the riboflavin piece. It is the shortest route to understanding why the largest number on this bottle is also the safest one on it.
• If you compare labels for a living, read the notation piece. Four ways of stating an amount, three of which a reader will misread without being told the difference.
• If you arrived from the seller’s order page, read the last one. Two documents describe two audiences and only one of them is a restriction anybody has to follow.

None of the five needs the others and all five assume you have read nothing else on this website. The panel they all start from is transcribed in full on the label page.

Four tests, and a draft that fails any of them does not go up. Two pieces were dropped at this stage and their subjects are named above.

• It starts from something printed. A panel row, a caution line, a distributor block. Not a claim on a sales page, and not a question a keyword tool suggested.
• Every number in it can be traced. To the label, to this desk’s own records, or to a paper fetched from the publisher. No figure in any of the five was estimated, and where a cited record does not state a dose the piece says so rather than calculating one.
• It is useful to somebody who buys nothing. That is the test a journal on a retail website has to pass to be worth publishing at all, and it is why two of the five end by pointing a reader at a different product.
• It does not repeat a money page. The guarantee, the pricing and the timeline each live in exactly one place on this website, and a piece that duplicated one of them would be padding dressed as an article.

If a line in any of the five is wrong, that is this desk’s problem rather than yours, and the website desk will change the page rather than argue about it.

One last note on length. Each of the five runs between fifteen hundred and eighteen hundred words, which is longer than most things written about a supplement and shorter than most things written about a single trial. That range is deliberate: it is roughly what it takes to quote a panel row, describe the study behind it, do the arithmetic between the two in public, and say what a reader should do about the answer. Anything shorter has skipped one of those four steps, and on this estate the step that gets skipped is nearly always the arithmetic.